共 50 条
- [21] Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data ONCOTARGETS AND THERAPY, 2020, 13 : 5199 - 5205
- [24] Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S288 - S288
- [25] Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (04): : e130 - e137
- [27] Tagraxofusp, an Anti-CD123 Therapy, in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm: Sub-Analysis of a Pivotal Trial by Age and Baseline Disease Involvement CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S254 - S254
- [28] Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123Targeted Therapy CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S244 - S245